Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 2/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
| ▸ | HTR1B | P28222 | 2/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29926359 | 1.00 | HRH3 (0.47) | HRH3MEN1THRBHTTKMT2A | |
| SCHEMBL27805443 | 1.00 | HRH3 (0.47) | HRH3MEN1THRBHTTKMT2A | |
| SCHEMBL8462300 | 0.97 | HRH3 (0.48) | HRH3MEN1THRBHTTKMT2A | |
| SCHEMBL25939787 | 0.95 | HRH3 (0.44) | HRH3MEN1THRBHTTKMT2A | |
| SCHEMBL14586412 | 0.92 | HRH3 (0.46) | HRH3MEN1THRBHTTKMT2A | |
| SCHEMBL23014750 | 0.90 | HRH3 (0.42) | HRH3MEN1THRBHTTKMT2A | |
| SCHEMBL16491133 | 0.90 | HTT (0.52) | HRH3MEN1THRBHTTKMT2A | |
| SCHEMBL13629121 | 0.90 | HRH3 (0.42) | HRH3MEN1THRBHTTKMT2A | |
| SCHEMBL12300027 | 0.90 | HTT (0.52) | HRH3MEN1THRBHTTKMT2A | |
| SCHEMBL19420781 | 0.88 | HRH3 (0.41) | HRH3MEN1THRBHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186531-B2 | Production method for alkene | KUREHA CORPORATION (JP) | 2021-11-30 | — | — | US | disclosed |
| US-20210047252-A1 | PRODUCTION METHOD FOR ALKENE | KUREHA CORPORATION (JP) | 2021-02-18 | — | — | US | disclosed |
| US-7638585-B2 | Catalyst flow | BASF CATALYSTS, LLC (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090286942-A1 | CATALYST FLOW | BASF CATALYSTS LLC (US) | 2009-11-19 | — | — | US | disclosed |
| US-7135531-B2 | Spherical catalyst for olefin polymerization | BASF CATALYSTS LLC (US) | 2006-11-14 | — | — | US | disclosed |
| US-20050176900-A1 | Spherical catalyst for olefin polymerization | ENGELHARD CORPORATION | 2005-08-11 | — | — | US | disclosed |
| EP-0284005-B1 | METHOD OF PRODUCTION OF POLYOLEFINS | IDEMITSU PETROCHEMICAL CO. LTD. (JP) | 1991-12-18 | — | — | EP | disclosed |
| US-4981930-A | POLYMERIZATION CATALYSTS | IDEMITSU PETROCHEMICAL COMPANY LIMITED (JP) | 1991-01-01 | — | — | US | disclosed |
| EP-0284005-A2 | Method of production of polyolefins | IDEMITSU PETROCHEMICAL CO. LTD. (JP) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047252-A1 | PRODUCTION METHOD FOR ALKENE | ALK, ALKBH3, ALKBH1 | HRH3 1387/4885MEN1 4564/4885THRB 4240/4885 |
| US-11186531-B2 | Production method for alkene | ALK, ALKBH3, ALKBH1 | HRH3 1387/4885MEN1 4564/4885THRB 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.